Experienced in Brain Tumor

Adrian F. Ochsenbein

Bern, BE, CH 
Experienced in Brain Tumor
Bern, BE, CH 
OverviewLocationsClinical Research

Overview

Adrian Ochsenbein practices in Bern, Switzerland. Mr. Ochsenbein is rated as an Experienced expert by MediFind in the treatment of Brain Tumor. His top areas of expertise are Leukemia, Chronic Myelogenous Leukemia (CML), Non-Small Cell Lung Cancer (NSCLC), and Acute Myeloid Leukemia (AML).

His clinical research consists of co-authoring 82 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Brain Tumor.

Gender
Male

Locations

Bern, BE 3008, Switzerland
Other Locations
Zurich, ZH 8091, Switzerland
Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.
Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drug: MEDI4736
Study Phase: Phase 2
A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma
A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: August 24, 2022
Intervention Type: Drug
Study Drugs: Pembrolizumab, Gemcitabine, Vinorelbine
Study Phase: Phase 3
View 2 Less Clinical Trials

82 Total Publications

Immune checkpoints regulate acute myeloid leukemia stem cells.
Immune checkpoints regulate acute myeloid leukemia stem cells.
Journal: Leukemia
Published: November 21, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ochsenbein's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile